Avecho Biotechnology Limited (ASX:AVE)
Australia · Delayed Price · Currency is AUD 0.0220
+0.0010 (4.76%)
Sep 11, 2026, 12:09 PM AEST
Avecho Biotechnology Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.74 | 1.24 | 1.13 | 0.47 | 1.13 | 0.79 | |
Revenue Growth | -46.59% | 9.28% | 139.19% | -58.06% | 42.30% | 106.33% |
Cost of Revenue | 0.2 | 0.35 | 0.46 | 0.52 | 0.34 | 0.29 |
Gross Profit | 0.54 | 0.89 | 0.67 | -0.04 | 0.79 | 0.51 |
Selling, General & Admin | 2.36 | 2.58 | 2.04 | 2.43 | 2.26 | 2.92 |
Research & Development | 1.4 | 2.26 | 1.7 | 0.95 | 0.87 | 0.99 |
Operating Expenses | 3.76 | 4.84 | 3.74 | 3.38 | 3.13 | 3.91 |
Operating Income | -3.22 | -3.96 | -3.06 | -3.42 | -2.34 | -3.41 |
Interest Expense | -0.44 | -0.46 | -0.06 | -0.02 | -0.01 | -0.01 |
EBT Excluding Unusual Items | -3.66 | -4.42 | -3.12 | -3.44 | -2.34 | -3.42 |
Pretax Income | -3.66 | -4.42 | -3.12 | -3.44 | -2.34 | -3.42 |
Earnings From Continuing Operations | -3.66 | -4.42 | -3.12 | -3.44 | -2.34 | -3.42 |
Net Income | -3.66 | -4.42 | -3.12 | -3.44 | -2.34 | -3.42 |
Net Income to Common | -3.66 | -4.42 | -3.12 | -3.44 | -2.34 | -3.42 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3,540 | 3,267 | 3,169 | 2,268 | 1,838 | 1,802 |
Shares Outstanding (Diluted) | 3,540 | 3,267 | 3,169 | 2,268 | 1,838 | 1,802 |
Shares Change | 11.67% | 3.08% | 39.73% | 23.41% | 1.97% | 13.27% |
EPS (Basic) | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EPS (Diluted) | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -3.59 | 1.1 | -3.97 | -3.18 | -1.72 | -3.3 |
Free Cash Flow Per Share | -0.00 | - | -0.00 | -0.00 | -0.00 | -0.00 |
Gross Margin | 72.91% | 71.77% | 59.32% | -9.25% | 70.23% | 64.00% |
Operating Margin | -437.05% | -319.55% | -270.59% | -722.46% | -206.86% | -429.20% |
Profit Margin | -496.99% | -356.82% | -275.64% | -725.70% | -207.43% | -430.46% |
Free Cash Flow Margin | -487.21% | 89.12% | -350.38% | -671.51% | -152.16% | -416.01% |
EBITDA | -3.1 | -3.82 | -2.92 | -3.24 | -2.11 | -2.98 |
EBITDA Margin | - | - | -257.80% | - | -186.47% | - |
D&A For EBITDA | 0.12 | 0.14 | 0.14 | 0.18 | 0.23 | 0.43 |
EBIT | -3.22 | -3.96 | -3.06 | -3.42 | -2.34 | -3.41 |
EBIT Margin | - | - | -270.59% | - | -206.86% | - |